Refractory Shapes IPO opens for subscription on May 6, with a price band of ₹27 to ₹31 per share. Lot size is 4,000 shares.

The length of their refractory period can vary hugely from person to person, but in general, it lasts somewhere between a few ...

Refractory Shapes IPO aims to raise Rs 18.6 crore, listing on NSE SME platform. Subscription from tomorrow to May 9. Offers ...

The initial public offering of Refractory Shapes opens for the public subscription today. Shares of Refractory Shapes are ...

The Mumbai-based company has set the price band of the upcoming IPO at ₹27 to ₹31 per share. Retail investors must invest a ...

Refractory Erectile dysfunction is more common in long standing diabetics, smokers and men with spinal trauma and other ...

GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based ...

Darzalex (daratumumab) is a monoclonal antibody drug currently approved for both refractory and new multiple myeloma. It’s available in intravenous and subcutaneous formulations.

Additionally, by the end of this year we plan to present initial dose escalation data for CB-011 in relapsed or refractory multiple myeloma.” Clinical highlights CB-010, a clinical-stage allogeneic ...

OJEMDA™ (tovorafenib) launch underway following U.S. FDA accelerated approval for relapsed or refractory BRAF-altered Pediatric Low-Grade Glioma ...

ADC Therapeutics is positioning Zynlonta for a label expansion with new Phase II data showing that the treatment can elicit high rates of complete response in patients with relapsed or refractory ...

Patients with TP53/PPM1D mutations in their stem cell product had an increased risk of myeloid neoplasms in patients with ...